Candidemia is the one of the most common form of invasive candidiasis, and in some countries the most common causes of bloodstream infections in hospitalized patients. In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss the prognosis of candidemia, the unmet needs in its treatment, and current recommended treatments.
Interviews available in this series:
Candidemia prognosis and unmet needs in its treatment
Guideline adherence predicts outcomes of candidemia in Europe
Questions:
- Could you tell us a little about candidemia, its prognosis and the unmet needs in its treatment?
- What is the recommended treatment for candidemia?
Disclosures: Martin Hoenigl is a consultant for Scynexis, Pulmocide, Gilead, Euro Pharma Holings, and Mundipharma; receives grant/research support from Gilead, Scynexis, Pfizer, MSD, Euroimun, and Mundipharma; and is on the advisory board for F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
